This is a working overview of PNB-0408, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
== Literatur == P. A. Gurnev, E. M. Nestorovich: Channel-forming bacterial toxins in biosensing and macromolecule delivery. In: Toxins. Band 6, Nummer 8, August 2014, S. 2483–2540, doi:10.3390/toxins6082483, PMID 25153255, PMC 4147595 (freier Volltext).
== Eigenschaften == Als Defensin ist β-Defensin ein antimikrobielles Peptid, das im Zuge der Immunantwort verstärkt gebildet wird. β-Defensin wird von Neutrophilen und Epithelzellen in der Haut und den Atemwegen gebildet. Es wirkt gegen Pilze der Gattung Candida und Gram-negative Bakterien. β-Defensin bindet an CCR6 und löst in den CCR6-tragenden Zellen eine Chemotaxis aus. Unterhalb einer Konzentration von 2,4 mM liegt es als Monomer vor.
== Eigenschaften == κ-Bungarotoxin wird in der Giftdrüse gebildet. Es bindet und hemmt nikotinische Acetylcholinrezeptoren mit einer IC50 von 100 nM. Es ist ein reversibler Antagonist insbesondere von alpha-3/CHRNA3 und in geringerem Umfang von alpha-4/CHRNA4-Acetylcholinrezeptoren. Im Gegensatz zum verwandten α-Bungarotoxin hemmt κ-Bungarotoxin das ganglion ciliare von Hühnern, weshalb es in der Reihe mit den anderen Bungarotoxinen mit dem griechischen Buchstaben 'κ' (als Allusion auf das lateinische ciliare) bezeichnet wurde. Wie das α-Bungarotoxin wirkt κ-Bungarotoxin postsynaptisch, während β-Bungarotoxin präsynaptisch wirkt.
== Eigenschaften == Hefutoxin ist ein Protein und Skorpiontoxin aus dem Skorpion Heterometrus fulvipes, wie auch κ-Hefutoxin 2. Es verlangsamt die Aktivierung des Kaliumkanals Kv1.3/KCNA3 und hemmt Kv1.3/KCNA3 und Kv1.2/KCNA2, nicht aber Kv1.1/KCNA1. Zu den Toxinen κ-Hefutoxin 1 und 2 sind keine strukturell verwandten Proteine bekannt.
Sources: de.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.